Pirlimycin
Chemical compound
- QJ51FF90 (WHO)
- Methyl (2S-cis)-7-chloro-6,7,8-trideoxy-6[[(4-ethyl-2-piperidinyl)carbonyl]amino]-1-thio-L-threo-α-D-galacto-octopyranoside
- 79548-73-5 Y
- 138508 N
- LM19JT6G5K
- D08391 Y
- ChEMBL1652611 N
- DTXSID30904249
- Interactive image
- CC[C@@H]1CCN[C@@H](C1)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl
InChI
- InChI=1S/C17H31ClN2O5S/c1-4-9-5-6-19-10(7-9)16(24)20-11(8(2)18)15-13(22)12(21)14(23)17(25-15)26-3/h8-15,17,19,21-23H,4-7H2,1-3H3,(H,20,24)/t8-,9+,10-,11+,12-,13+,14+,15+,17+/m0/s1 N
- Key:HBJOXQRURQPDEX-MHXMMLMNSA-N N
Pirlimycin hydrochloride belongs to the lincosamide class of antimicrobials. Under the trade name Pirsue,[1] it is used in the treatment of mastitis in cattle.[2][3]
Activity
Pirlimycin is active against Gram-positive bacteria, specifically Staphylococcus aureus and coagulase negative species of Staphylococcus and Streptococcus. It has no activity against Gram-negative bacteria.[4]
Mechanism of action
It is bacteriostatic and acts by inhibiting bacterial protein synthesis via binding with the 50S subunit of the ribosome.[citation needed]
References
- ^ Pirsue Sterile Solution
- ^ Thornsberry C, Marler JK, Watts JL, Yancey RJ (May 1993). "Activity of pirlimycin against pathogens from cows with mastitis and recommendations for disk diffusion tests". Antimicrobial Agents and Chemotherapy. 37 (5): 1122–6. doi:10.1128/AAC.37.5.1122. PMC 187914. PMID 8517701.
- ^ Hogeveen H (2005). Mastitis in dairy production: current knowledge and future solutions. Wageningen: Wageningen Academic Publishers. p. 55. ISBN 978-90-76998-70-1.
- ^ "USP: Pirlimycin" (PDF). Archived from the original (PDF) on 2009-05-09. Retrieved 2009-06-28.
- v
- t
- e
Aminoglycosides (initiation inhibitors) |
| ||||||
---|---|---|---|---|---|---|---|
Tetracycline antibiotics (tRNA binding) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e